Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Niuton Koide

Clinical Cardiac Electrophysiology Las Vegas, NV Medical Doctor

NPI 1821067059 CMS profile 218146

2880 N Tenaya Way Ste 100, Ste 100, Las Vegas, NV 89128

Open in the dashboard

General payments

$33,589

505 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$9,631 paid to institutions, not to them · program year 2019

Through program year 2025, Niuton Koide of Las Vegas, NV is reported in the CMS Open Payments database as having received $33,589 across 505 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $9,631 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 65th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,879 137
2024 General $2,570 75
2023 General $4,492 75
2022 General $3,545 74
2021 General $7,251 65
2020 General $1,801 26
2019 General $7,051 53

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Niuton Koide
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Niuton Koide were reported at $6,879. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Niuton Koide Clinical Cardiac Electrophysiology median Middle half National median
2019 $7,051 $2,361 $585–$8,260 $163
2020 $1,801 $993 $247–$4,351 $114
2021 $7,251 $1,185 $326–$4,739 $132
2022 $3,545 $2,073 $554–$6,789 $149
2023 $4,492 $2,568 $759–$8,159 $160
2024 $2,570 $2,557 $703–$7,403 $164
2025 $6,879 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $16,858 106 payments
  2. Medtronic, Inc. $6,548 107 payments
  3. Atricure, Inc. $1,453 8 payments
  4. Medtronic Vascular, Inc. $1,408 22 payments
  5. Boston Scientific Corporation $1,165 32 payments
  6. Novartis Pharmaceuticals Corporation $1,063 49 payments
  7. Biosense Webster, Inc. $521 8 payments
  8. Medical Device Business Services, Inc. $473 7 payments
  9. Amgen Inc. $434 29 payments
  10. E.R. Squibb & Sons, L.L.C. $430 22 payments
  11. Other $3,235 115 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $22,318 463 payments
  2. Travel and Lodging $6,917 34 payments
  3. Consulting Fee $4,296 7 payments
  4. Education $58 1 payment
Products named General payments · program years 2019–2025
  1. Ensite Cardiac Mapping System $3,870 11 payments
  2. AVEIR Structural Heart $2,510 14 payments
  3. AVEIR Cardiac Rhythm Management $1,891 12 payments
  4. EnSite Precision Cardiac Mapping System $1,890 5 payments
  5. ATRICLIP LAA EXCLUSION SYSTEM $1,286 6 payments
  6. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $1,280 6 payments
  7. ISOLATOR SURGICAL ABLATION SYSTEM $1,261 5 payments
  8. DISSECTOR $1,261 5 payments
  9. SYNERGY ABLATION SYSTEM $1,261 5 payments
  10. Micra $833 9 payments
  11. Other $20,225 464 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,080

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$414,450

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

32.2%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 151 $198,760
Xarelto Rivaroxaban Brand 102 $131,128
Entresto Sacubitril/Valsartan Brand 42 $65,630
Mexiletine Hcl Generic 33 $5,426
Dofetilide Generic 18 $2,917
Propafenone Hcl Generic 28 $2,591
Amiodarone Hcl Generic 78 $1,402
Metoprolol Succinate Generic 105 $1,211
Flecainide Acetate Generic 27 $858
Sotalol Sotalol Hcl Brand 37 $644

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 74 billing codes

Paid by Medicare

$254,326

Medicare's payments for the services billed

Medicare patients

1,612

Average age 75

Services billed

4,704

807 women, 805 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 52%
Atrial fibrillation 51%
Diabetes 45%
Heart failure 45%
Chronic kidney disease 44%
COPD 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $133
$133 — —
Repatha
  • Amgen Inc. $104
$104 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $78
$78 — —
ELIQUIS
  • PFIZER INC. $40
  • E.R. Squibb & Sons, L.L.C. $25
$65 151 —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $62
$62 42 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

505 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record